MSB Trading 2020 - a new dawn, page-264

To state the obvious, we are about to see a massive short squeeze.

And for those who reckon a lot of those shorts are just long funds who have hedged, yes that may have some truth to it, but they have now no reason to hedge and they are just costing themselves tremendous upside, so they will also be some of the first to exit as their business case worked out and this is not the end of the revaluation, just the beginning.

Now, the US investors will find out about the this MESO because only FDA/US companies have any meaning to some of those guys. That WS article is just the start. What will those lemmings do when they learn a product is about to be approved which is also on the cusp of a phase 3 trial for covid ards? It could be a 'Kodak' moment thanks to those sharts.